Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Hepatitis B Healthy adult, aged between 20 to 45 years old. 2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests, chest x-ray and electrocardiogram no particular clinical significance in clinical examination and laboratory tests within two months (60 days) prior to administration of study medication normal or considered not clinically significant by the investigator chest X-ray and Electrocardiogram (ECG) results within six months(180 days)prior to administration of study medication. 3. Body weight must be above 50 kg for male and 45 kg for female. 4. The normal range of the body mass index should be between 18 and 30; body mass index equals [weight (kg)]/[height (m)]2. 5. Laboratory determinations results are within normal range or considered not clinically significant by the investigator, including: Serum Glutamic Oxaloacetic Transaminase (SGOT, same as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as ALT), albumin, glucose, creatinine, uric acid, cholesterol, Triglycerides (TG), Gamma-Glutamyl-Transpeptidase (γ-GT), alkaline phosphatase, total bilirubin, Blood Urea Nitrogen (BUN), Hepatitis B surface antigen (HBsAg), Anti-Hepatitis C virus (HCV) and Anti-Human Immunodeficiency Virus (HIV) test. 6. Hematology test results are within normal range or considered not clinically significant by the investigator, including: hemoglobin, hematocrit, White Blood Cell (WBC) count, Red Blood Cell (RBC) count, platelet count and WBC count with differential. 7. Urinalysis results are within normal range or considered not clinically significant by the investigator, including: glucose, protein, RBC, WBC, epithelial cells, casts and bacteria. 8. Female subject who is using adequate contraception since last menstruation and no plan for conception during the study non-lactating has negative pregnancy test (urine) prior to the study. 9. Informed consent form signed  A history of drug or alcohol abuse during the past 24 weeks. 2. Sensitivity to analogous drug. 3. A clinically significant illness (such as lactic acidosis or severe hepatomegaly with steatosis) within the past 4 weeks. 4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal pathology within the past 4 weeks. 5. Planned vaccination during the time course of the study. 6. Participation of any clinical investigation during the last 60 days. 7. Regular use of any medication during the last 4 weeks. 8. Single use of any medication during the last 2 weeks. 9. Blood donation of more than 250 mL within the past 12 weeks. 10. Employees and their families of sponsor and/or Contract Research Organization (CRO) company. 11. Individuals are judged by the investigator or co-investigator to be undesirable as subjects